search
Back to results

Study of TL-895 in Subjects With Myelofibrosis

Primary Purpose

Myelofibrosis

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
TL-895
Sponsored by
Telios Pharma, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myelofibrosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults ≥18 years of age
  • Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria
  • Palpable spleen measuring ≥5 cm below the LLCM or spleen volume of ≥450 cm³ by MRI or CT scan assessment
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • Adequate hematologic, hepatic, and renal functions

Exclusion Criteria:

  • Prior treatment with any BTK or BMX inhibitors
  • Cohorts 1 and 2 - Prior treatment with JAKi within 21 days of the Screening MRI/CT scan. Subjects in Cohort 3 must not have received JAKi
  • Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment

Sites / Locations

  • University of Colorado - Aurora Cancer CenterRecruiting
  • University of MarylandRecruiting
  • Gabrail Cancer CenterRecruiting
  • University of Cincinnati (UC) Physicians Company, LLCRecruiting
  • Ohio State UniversityRecruiting
  • University of Texas, MD Anderson Cancer CenterRecruiting
  • Border Medical OncologyRecruiting
  • Southern Oncology SpecialistsRecruiting
  • South Eastern Private HospitalRecruiting
  • Royal Perth HospitalRecruiting
  • St Vincent's Hospital SydneyRecruiting
  • Chu De LiègeRecruiting
  • Cliniques Universitaires Saint-LucRecruiting
  • Hospital de Clinicas de Porto AlegreRecruiting
  • Hematologista e Pesquisadora Clínica Hospital A Beneficência PortuguesRecruiting
  • Universidade de Sao Paulo - Hospital das Clinicas da Faculdade de MedicinaRecruiting
  • Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao LucasRecruiting
  • University Hospital "St Ivan Rilski"Recruiting
  • National Specialized Hospital for Active Treatment of Hematological DiseasesRecruiting
  • CHRU de Brest - Hôpital MorvanRecruiting
  • CH Le MansRecruiting
  • CHU de Nantes - Hôtel-DieuRecruiting
  • CHU de Nice - Hopital L' Archet IIRecruiting
  • Hôpital Saint-Louis AP-HPRecruiting
  • Universitaetsklinikum Carl Gustav Carus DresdenRecruiting
  • Marien Hospital DuesseldorfRecruiting
  • Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum HallRecruiting
  • Universitaetsklinikum JenaRecruiting
  • Praxisklinik fur Hamatologie und OnkologieRecruiting
  • Debreceni Egyetem Klinikai KozpontRecruiting
  • Markhot Ferenc Oktatokorhaz es RendelointezetRecruiting
  • Petz Aladar Egyetemi Oktato KorhazRecruiting
  • Somogy Megyei Kaposi Mor Oktato KorhazRecruiting
  • Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktatókórház Megyei-Városi Tüdőgondozó IntézeteRecruiting
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato KorhazRecruiting
  • Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. RodolicoRecruiting
  • Presidio Ospedaliero Gaspare RodolicoRecruiting
  • Istituto Romagnolo per lo Studio dei Tumori Dino AmadoriRecruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MilanoRecruiting
  • ASST Grande Ospedale Metropolitano NiguardaRecruiting
  • Azienda Ospedaliero Universitaria Maggiore Della Carita'Recruiting
  • Azienda Ospedaliera di Perugia-Ospedale S. Maria della MisericordiaRecruiting
  • AUSL della Romagna-Ospedale S.Maria delle CrociRecruiting
  • Grande Ospedale Metropolitano Bianchi Melacrino MorelliRecruiting
  • Azienda Ospedaliero Universitaria Policlinico Umberto IRecruiting
  • Ospedale dell'AngeloRecruiting
  • Kyungpook National University HospitalRecruiting
  • Asan Medical CenterRecruiting
  • Samsung Medical CenterRecruiting
  • Seoul National University HospitalRecruiting
  • Seoul St. Mary's Hospital, The Catholic University of KoreaRecruiting
  • Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Klinika HematologiRecruiting
  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i TransplantologiiRecruiting
  • Klinika Hematologii Collegium Medicum Uniwersytetu JagiellonskiegoRecruiting
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Klinika Hematologii, Nowotworów Krwi i Transplantacji SzpikuRecruiting
  • Hospital de la Santa Creu i Sant PauRecruiting
  • Institut Catala d'Oncologia - L'HospitaletRecruiting
  • Hospital Germans Trias i PujolRecruiting
  • Hospital Universitari Arnau de VilanovaRecruiting
  • Hospital Universitario 12 de OctubreRecruiting
  • Hospital Universitario Virgen de la VictoriaRecruiting
  • Salamanca University HospitalRecruiting
  • Hospital Quirónsalud ZaragozaRecruiting
  • Chang Gung Memorial Hospital - Kaohsiung BranchRecruiting
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)Recruiting
  • China Medical University HospitalRecruiting
  • National Taiwan University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort 1a, Relapsed/Refractory Myelofibrosis

Cohort 1b, Relapsed/Refractory Myelofibrosis

Cohort 1c, Relapsed/Refractory Myelofibrosis

Cohort 1d, Relapsed/Refractory Myelofibrosis

Cohort 2a, JAKi Intolerant Myelofibrosis

Cohort 2b, JAKi Intolerant Myelofibrosis

Cohort 3a, JAKi Ineligible Myelofibrosis

Cohort 3b, JAKi Ineligible Myelofibrosis

Cohort 1 Expansion, Relapsed/Refractory Myelofibrosis

Cohort 3 Expansion, JAKi Ineligible Myelofibrosis

Arm Description

150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.

300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.

300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.

450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.

150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.

300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.

150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.

300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.

TL-895 administered orally at RP2D and schedule

TL-895 administered orally at RP2D and schedule

Outcomes

Primary Outcome Measures

Primary Objective, Part A: To determine the RP2D of TL-895 in each cohort.
The safety review committee (SRC) will determine the RP2D for Cohorts 1, 2 and 3 based on safety and tolerability data obtained from each arm of that cohort.
Primary Objective, Part B: To determine the spleen volume reduction (SVR) rate at Week 24.
The proportion of subjects achieving ≥35% SVR at Week 24 by MRI or CT scan (central review).

Secondary Outcome Measures

Key Secondary Objective: Improvement in Total Symptom Score at Week 24.
The proportion of subjects achieving ≥50% reduction in Total Symptom Score at Week 24 by MFSAF v4.0.
Key Secondary Objective: To determine the duration of response (DOR).
Time from initial response to progression.
Key Secondary Objective: To determine the progression-free survival (PFS).
Time from the first dose to progression or death from any cause.
Key Secondary Objective: To determine the duration overall response (OS).
Time from the first dose to death of any cause.

Full Information

First Posted
November 24, 2020
Last Updated
October 11, 2022
Sponsor
Telios Pharma, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04655118
Brief Title
Study of TL-895 in Subjects With Myelofibrosis
Official Title
A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 22, 2020 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Telios Pharma, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelofibrosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
149 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1a, Relapsed/Refractory Myelofibrosis
Arm Type
Experimental
Arm Description
150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 1b, Relapsed/Refractory Myelofibrosis
Arm Type
Experimental
Arm Description
300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 1c, Relapsed/Refractory Myelofibrosis
Arm Type
Experimental
Arm Description
300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 1d, Relapsed/Refractory Myelofibrosis
Arm Type
Experimental
Arm Description
450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 2a, JAKi Intolerant Myelofibrosis
Arm Type
Experimental
Arm Description
150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 2b, JAKi Intolerant Myelofibrosis
Arm Type
Experimental
Arm Description
300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 3a, JAKi Ineligible Myelofibrosis
Arm Type
Experimental
Arm Description
150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 3b, JAKi Ineligible Myelofibrosis
Arm Type
Experimental
Arm Description
300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
Arm Title
Cohort 1 Expansion, Relapsed/Refractory Myelofibrosis
Arm Type
Experimental
Arm Description
TL-895 administered orally at RP2D and schedule
Arm Title
Cohort 3 Expansion, JAKi Ineligible Myelofibrosis
Arm Type
Experimental
Arm Description
TL-895 administered orally at RP2D and schedule
Intervention Type
Drug
Intervention Name(s)
TL-895
Intervention Description
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
Primary Outcome Measure Information:
Title
Primary Objective, Part A: To determine the RP2D of TL-895 in each cohort.
Description
The safety review committee (SRC) will determine the RP2D for Cohorts 1, 2 and 3 based on safety and tolerability data obtained from each arm of that cohort.
Time Frame
9 months
Title
Primary Objective, Part B: To determine the spleen volume reduction (SVR) rate at Week 24.
Description
The proportion of subjects achieving ≥35% SVR at Week 24 by MRI or CT scan (central review).
Time Frame
Week 24
Secondary Outcome Measure Information:
Title
Key Secondary Objective: Improvement in Total Symptom Score at Week 24.
Description
The proportion of subjects achieving ≥50% reduction in Total Symptom Score at Week 24 by MFSAF v4.0.
Time Frame
Week 24
Title
Key Secondary Objective: To determine the duration of response (DOR).
Description
Time from initial response to progression.
Time Frame
44 months
Title
Key Secondary Objective: To determine the progression-free survival (PFS).
Description
Time from the first dose to progression or death from any cause.
Time Frame
44 months
Title
Key Secondary Objective: To determine the duration overall response (OS).
Description
Time from the first dose to death of any cause.
Time Frame
44 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults ≥18 years of age Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria Palpable spleen measuring ≥5 cm below the LLCM or spleen volume of ≥450 cm³ by MRI or CT scan assessment Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 Adequate hematologic, hepatic, and renal functions Exclusion Criteria: Prior treatment with any BTK or BMX inhibitors Cohorts 1 and 2 - Prior treatment with JAKi within 21 days of the Screening MRI/CT scan. Subjects in Cohort 3 must not have received JAKi Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
John Mei
Phone
650-542-0136
Email
jmei@teliospharma.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sherry Toney
Email
SToney@teliospharma.com
Facility Information:
Facility Name
University of Colorado - Aurora Cancer Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Maryland
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Individual Site Status
Recruiting
Facility Name
Gabrail Cancer Center
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Cincinnati (UC) Physicians Company, LLC
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Individual Site Status
Recruiting
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Texas, MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Border Medical Oncology
City
East Albury
Country
Australia
Individual Site Status
Recruiting
Facility Name
Southern Oncology Specialists
City
Kogarah
ZIP/Postal Code
2217
Country
Australia
Individual Site Status
Recruiting
Facility Name
South Eastern Private Hospital
City
Noble Park
Country
Australia
Individual Site Status
Recruiting
Facility Name
Royal Perth Hospital
City
Perth
ZIP/Postal Code
6000
Country
Australia
Individual Site Status
Recruiting
Facility Name
St Vincent's Hospital Sydney
City
Sydney
ZIP/Postal Code
2010
Country
Australia
Individual Site Status
Recruiting
Facility Name
Chu De Liège
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Cliniques Universitaires Saint-Luc
City
Woluwe-Saint-Lambert
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Hospital de Clinicas de Porto Alegre
City
Porto Alegre
ZIP/Postal Code
90035
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hematologista e Pesquisadora Clínica Hospital A Beneficência Portugues
City
São Paulo
ZIP/Postal Code
01323
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Universidade de Sao Paulo - Hospital das Clinicas da Faculdade de Medicina
City
São Paulo
ZIP/Postal Code
05403
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao Lucas
City
São Paulo
ZIP/Postal Code
76805
Country
Brazil
Individual Site Status
Recruiting
Facility Name
University Hospital "St Ivan Rilski"
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
National Specialized Hospital for Active Treatment of Hematological Diseases
City
Sofia
ZIP/Postal Code
1756
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
CHRU de Brest - Hôpital Morvan
City
Brest
ZIP/Postal Code
29200
Country
France
Individual Site Status
Recruiting
Facility Name
CH Le Mans
City
Le Mans
ZIP/Postal Code
72037
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Nantes - Hôtel-Dieu
City
Nantes
ZIP/Postal Code
44000
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Nice - Hopital L' Archet II
City
Nice
ZIP/Postal Code
06200
Country
France
Individual Site Status
Recruiting
Facility Name
Hôpital Saint-Louis AP-HP
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Recruiting
Facility Name
Universitaetsklinikum Carl Gustav Carus Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Name
Marien Hospital Duesseldorf
City
Düsseldorf
ZIP/Postal Code
40479
Country
Germany
Individual Site Status
Recruiting
Facility Name
Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall
City
Halle
ZIP/Postal Code
07747
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitaetsklinikum Jena
City
Jena
ZIP/Postal Code
07743
Country
Germany
Individual Site Status
Recruiting
Facility Name
Praxisklinik fur Hamatologie und Onkologie
City
Koblenz
ZIP/Postal Code
56073
Country
Germany
Individual Site Status
Recruiting
Facility Name
Debreceni Egyetem Klinikai Kozpont
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Markhot Ferenc Oktatokorhaz es Rendelointezet
City
Eger
ZIP/Postal Code
3300
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Petz Aladar Egyetemi Oktato Korhaz
City
Győr
ZIP/Postal Code
9024
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Somogy Megyei Kaposi Mor Oktato Korhaz
City
Kaposvár
ZIP/Postal Code
7400
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktatókórház Megyei-Városi Tüdőgondozó Intézete
City
Nyíregyháza
ZIP/Postal Code
4400
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
City
Székesfehérvár
ZIP/Postal Code
8000
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico
City
Catania
ZIP/Postal Code
95123
Country
Italy
Individual Site Status
Recruiting
Facility Name
Presidio Ospedaliero Gaspare Rodolico
City
Catania
ZIP/Postal Code
95125
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
City
Meldola
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
City
Milano
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Recruiting
Facility Name
ASST Grande Ospedale Metropolitano Niguarda
City
Milano
ZIP/Postal Code
20162
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero Universitaria Maggiore Della Carita'
City
Novara
ZIP/Postal Code
28100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia
City
Perugia
ZIP/Postal Code
06129
Country
Italy
Individual Site Status
Recruiting
Facility Name
AUSL della Romagna-Ospedale S.Maria delle Croci
City
Ravenna
ZIP/Postal Code
48121
Country
Italy
Individual Site Status
Recruiting
Facility Name
Grande Ospedale Metropolitano Bianchi Melacrino Morelli
City
Reggio Calabria
ZIP/Postal Code
89124
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero Universitaria Policlinico Umberto I
City
Roma
ZIP/Postal Code
00161
Country
Italy
Individual Site Status
Recruiting
Facility Name
Ospedale dell'Angelo
City
Venezia
ZIP/Postal Code
30174
Country
Italy
Individual Site Status
Recruiting
Facility Name
Kyungpook National University Hospital
City
Daegu
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Seoul St. Mary's Hospital, The Catholic University of Korea
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Klinika Hematologi
City
Bydgoszcz
ZIP/Postal Code
85-168
Country
Poland
Individual Site Status
Recruiting
Facility Name
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
City
Gdańsk
ZIP/Postal Code
80-211
Country
Poland
Individual Site Status
Recruiting
Facility Name
Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellonskiego
City
Kraków
ZIP/Postal Code
31-501
Country
Poland
Individual Site Status
Recruiting
Facility Name
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku
City
Wrocław
ZIP/Postal Code
52-007
Country
Poland
Individual Site Status
Recruiting
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Individual Site Status
Recruiting
Facility Name
Institut Catala d'Oncologia - L'Hospitalet
City
Barcelona
ZIP/Postal Code
08908
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Germans Trias i Pujol
City
Barcelona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Arnau de Vilanova
City
Lleida
ZIP/Postal Code
25198
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen de la Victoria
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Salamanca University Hospital
City
Salamanca
ZIP/Postal Code
37007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Quirónsalud Zaragoza
City
Zaragoza
ZIP/Postal Code
50006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Chang Gung Memorial Hospital - Kaohsiung Branch
City
Kaohsiung City
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
City
Kaohsiung
ZIP/Postal Code
80756
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Study of TL-895 in Subjects With Myelofibrosis

We'll reach out to this number within 24 hrs